BNP Paribas Asset Management
SNDX icon

BNP Paribas Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

BNP Paribas Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1M Buy
1,790,173
+57,632
+3% +$1.2M 0.04% 407
2026
Q1 		$40.5M Buy
1,732,541
+356,860
+26% +$7.75M 0.05% 370
2025
Q4 		$28.9M Buy
1,375,681
+139,604
+11% +$2.44M 0.03% 451
2025
Q3 		$19M Sell
1,236,077
-209,363
-14% -$2.74M 0.05% 359
2025
Q2 		$13.5M Buy
1,445,440
+224,171
+18% +$2.47M 0.03% 404
2025
Q1 		$15M Buy
1,221,269
+198,732
+19% +$2.8M 0.04% 389
2024
Q4 		$13.5M Buy
1,022,537
+234,752
+30% +$4.02M 0.03% 409
2024
Q3 		$15.2M Buy
+787,785
New +$16.3M 0.04% 363

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BNP Paribas Asset Management's SNDX Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Syndax Pharmaceuticals (SNDX) stake by 3.3% in Q2 2026, buying an estimated $1.2M and bringing the position to 1,790,173 shares worth $39.1M. The position accounts for 0.04% of the portfolio, ranked #407.

BNP Paribas Asset Management first reported a position in SNDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $40.5M in Q1 2026. 158 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • BNP Paribas Asset Management held 1,790,173 shares of Syndax Pharmaceuticals worth $39.1M as of Q2 2026.
  • BNP Paribas Asset Management bought 57,632 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.2M.
  • Syndax Pharmaceuticals made up 0.04% of BNP Paribas Asset Management's portfolio in Q2 2026, its #407 holding.
  • BNP Paribas Asset Management first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • BNP Paribas Asset Management's Syndax Pharmaceuticals position peaked at $40.5M in Q1 2026.
  • 158 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.